Variables | Correlation | Chi-square | P-value |
---|---|---|---|
Age | |||
15–24 | Reference | ||
25–34 | −0.016 | 0.069 | 0.791 |
35–44 | −0.004 | 0.004 | 0.947 |
≥ 45 | − 0.055 | 0.805 | 0.369 |
Gender | |||
Female | Reference | ||
male | 0.011 | 0.032 | 0.857 |
BMI(kg/m2) | |||
< 18.5 | −0.106 | 2.900 | 0.089 |
18.5–24.99 | Reference | ||
> 25 | 0.037 | 0.327 | 0.567 |
CD4 count at switch | |||
≥ 100 cells/mm3 | Reference | ||
< 100 cells/mm3 | −0.089 | 2.098 | 0.147 |
Regimen modification | |||
Yes | Reference | ||
No | 0.002 | 0.001 | 0.973 |
ART adherence | |||
Good | Reference | ||
Fair | 0.066 | 1.132 | 0.287 |
Poor | 0.079 | 1.612 | 0.204 |
WHO clinical stage | |||
I | Reference | ||
II | 0.045 | 0.519 | 0.471 |
III | 0.052 | 0.728 | 0.393 |
IV | 0.079 | 1.679 | 0.195 |
Isoniazid Preventive Therapy (INH) given | |||
Yes | Reference | ||
No | 0.013 | 0.044 | 0.833 |
Functional status at switch | |||
Working | Reference | ||
Ambulatory | −0.056 | 0.867 | 0.352 |
bedridden | −0.023 | 0.128 | 0.719 |
Opportunistic Infections (OI) | |||
Yes | Reference | ||
No | 0.093 | 2.290 | 0.130 |
Second-line regimen | |||
ABC-ddI-LPV/r | Reference | ||
TDF-3TC-LPV/r | −0.058 | 0.906 | 0.341 |
AZT-3TC-LPV/r | 0.017 | 0.072 | 0.788 |
Othersa | −0.077 | 1.512 | 0.219 |